Nature published an editorial supporting Kids vs. Cancer's bill to increase support for pediatric clinical trials.
Greg Curt died last Sunday. For us in oncology, this one was especially personal. He was a wonderful, generous young man. Greg was a beloved friend and colleague. He was an accomplished cancer researcher and leader in oncology who died of the disease we treat.
League tables like those published by U.S. News and World Report should probably be taken with a pinch of salt in any case, but it is the self-marketing of these tables that is just a bit problematic.
The U.S. News & World Report rankings of the best cancer hospitals for 2016 brought no great surprises. The top four remained unchanged from last year:
A phase III study evaluating Gazyva (obinutuzumab) plus CHOP chemotherapy in people with previously untreated diffuse large B-cell lymphoma did not meet its primary endpoint of progression-free survival compared to Rituxan (rituximab) plus CHOP chemotherapy, according to Genentech, a member of the Roche Group.
Positive results from a phase III trial in advanced colorectal cancer showed that Xilonix-treated patients with advanced disease and multiple symptoms known to inversely correlate with overall survival experienced a 76 percent relative increase in clinical response rate after eight weeks of therapy compared to placebo, at 33 percent vs. 19 percent, respectively (p=.0045).
The U.S. News & World Report rankings of the best cancer hospitals for 2016 brought no great surprises. The top four cancer centers did not change from last year:
When the Genomic Data Commons opened June 6, the $20 million portal that consolidates NCI's datasets contained genomic information from 14,500 patients.
A measure that authorizes the FDA to mandate companies developing cancer drugs for adults to also study their products in children when there is a matching molecular target was introduced in the House and Senate earlier this week.
Alfred G. Knudson Jr., the creator of the “two-hit hypothesis,” and a director of the Institute for Cancer Research at Fox Chase Cancer Center, died July 10. He was 93.
